Bifeprunox in the Treatment of Schizophrenia

A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-term Treatment of Schizpohrenia (Extension of S1543003)

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.

Inclusion Criteria:

• diagnosis of schizophrenia
• understand nature of study
• able to be managed in out-patient setting for long-term bifeprunox treatment

Exclusion Criteria:

• current primary diagnosis other than schizophrenia
• suicide risk
• diagnosis or history of substance abuse
• uncontrolled hypertension